New Vaccine Recommended for Pregnant Individuals to Prevent Severe Respiratory Illness in Infants
The CDC’s Advisory Committee on Immunization Practices (ACIP) has given the green light for the use of Abrysvo™, a vaccine aimed at preventing respiratory syncytial virus (RSV) in infants. This recommendation specifically targets pregnant individuals between 32 and 36 weeks of gestation, offering a new avenue for safeguarding infant health.
HCN Medical Memo
This recommendation opens up a new preventive strategy against RSV, a common cause of severe respiratory illness in infants. The endorsement of Abrysvo for maternal immunization provides an additional tool for clinicians to offer expectant parents, thereby potentially reducing the incidence of RSV-related complications in newborns.
- ACIP recommends Abrysvo for active immunization of pregnant individuals at 32 through 36 weeks gestational age.
- The vaccine aims to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth through 6 months.
- Abrysvo is an unadjuvanted bivalent vaccine containing recombinant RSV prefusion F (preF) A and RSV preF B.
- The recommendation is based on data from the phase 3 MATISSE trial.
- CDC Director Dr. Mandy Cohen encourages parents to consult with healthcare providers about RSV prevention options.
“This is another new tool we can use this fall and winter to help protect lives.”
– Dr. Mandy Cohen, CDC Director
- Abrysvo is available in a kit containing a vial of lyophilized antigen component, a prefilled syringe containing diluent, and a vial adapter.
- The vaccine is also indicated for the prevention of LRTD caused by RSV in individuals 60 years of age and older.
More on Vaccinations/Immunization